APA (7th ed.) Citation

Kienast, Y., & Augustin, H. (2013). Ang-2-VEGF-A crossmab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clinical cancer research, 19(24), .

Chicago Style (17th ed.) Citation

Kienast, Yvonne, and Hellmut Augustin. "Ang-2-VEGF-A Crossmab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy." Clinical Cancer Research 19, no. 24 (2013).

MLA (9th ed.) Citation

Kienast, Yvonne, and Hellmut Augustin. "Ang-2-VEGF-A Crossmab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy." Clinical Cancer Research, vol. 19, no. 24, 2013.